Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection

Viral Immunology

Volumn 18, Issue 1, 2005, Pages 197-204

  Neau Cransac, Martine ^a   Foucher, Juliette ^b,c   De Ledinghen, Victor ^b   Bernard, Pierre Henri ^c   Legrand, Elisabeth ^d   Lafon, Marie Edith ^d  

^a HÔPITAL PELLEGRIN   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE I, RECOMBINANT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RIBAVIRIN; T-LYMPHOCYTES; TIME FACTORS;

HEPATITIS C VIRUS;

EID: 17844388356     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2005.18.197     Document Type: Article

References (45)

1. Appasamy, R., J. Bryant, T. Hassanein, et al. 1994. Effects of therapy with interferon-α on peripheral blood lymphocytes subsets and NK activity in patients with chronic hepatitis C. Clin. Immunol. Immunopathol. 73:350-357.
2. Bain, C., A. Fatmi, F. Zoulim, et al. 2001. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120:512-524.
3. Barnes, E., G. Webster, S. Whalley, et al. 1999. Predictors of a favorable response to alpha interferon therapy for hepatitis C. Clin. Liver Dis. 3:775-791.
4. Bedossa, P., T. Poynard, for the METAVIR Cooperative Study Group. 1996. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24:289-293.
5. Cacoub, P., L. Musset, P. Hausfater, et al. 1998. No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Clin. Exp. Immunol. 113:48-54.
6. Cerny, A., and F.V. Chisari. 1999. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology 30:595-601.
7. + T-cell responsiveness in hepatitis C virus infection. Hepatology 33:267-276.
8. Cramp, M.E., S. Rossol, S. Chokshi, et al. 2000. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346-355.
9. EASL Internationnal Consensus Conference on Hepatitis C. 1999. Consensus Statement. J. Hepatol. 30:956-961.
10. + T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat. Med. 7:794-801.
11. Fried, M.W., M.L. Shiffman, K.R. Reddy, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C Virus infection. N. Engl. J. Med. 347:975-982.
12. Giovanetti, A., F. Mazetta, R. Coviello, et al. 2001. T-cell immune activation in children with vertically transmitted hepatitis C virus infection. Viral Immunol. 14:169-179.
13. Gresser, I., D. Guy-Grand, C. Maury, et al. 1981. Interferon induces peripheral lymphadenopathy in mice. J. Immunol. 127:1569-1575.
14. Hultgren, C., D.R. Milich, O. Weiland, et al. 1998. The antiviral compound ribavirin modulates the T helper (Th)1:Th2 subset balance in hepatitis B and virus-specific immune response. J. Gen. Virol. 79:2381-2391.
15. Kaser, A., S. Nagata, and H. Tilg. 1999. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 11:736-743.
16. Katze, M.G., Y. He, and M. Gale. 2002. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2:675-687.
17. Koziel, M.J., D. Dudley, J.T. Wong, et al. 1992. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C in persons with chronic hepatitis. J. Immunol. 149:3339-3344.
18. Lapinski, T.W., A. Kot, and D. Prokowicz. 2002. Concentration of β2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-α therapy. Med. Sci. Monit. 8:CR538-CR535.
19. Lechner, F., D.K.H. Wong, P.R. Dunbar, et al. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:1499-1512.
20. Lee, S.S., E.J. Heathcote, K.R. Reddy, et al. 2002. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 kd). J. Hepatol. 37:500-506.
21. Luft, T., K.C. Pang, E. Thomas, et al. 1998. Type I EFNs-alpha enhances the terminal differenciation of dendritic cells. J. Immunol. 161:1947-1953
22. McHutchinson, J.G., S.C. Gordon, E.R. Schiff, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
23. Manns, M.P., J.G. McHutchinson, S.C. Gordon, et al. 2001. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
24. Martin, J., S. Navas, J. Quiroga, et al. 1998. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 10:635-644.
25. Martinot-Peignoux, M., P. Marcellin, M. Pouteau, et al. 1995. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independant prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 22:1050-1056.
26. Missale, G., E. Cariani, V. Lamonaca, et al. 1997. Effects of interferon treatment on the anti-viral T cell response in hepatitis C virus genotype 1b and 2c-infected patients. Hepatology 26:792-797.
27. + T cells: do they help or damage? Gastroenterology 117:1012-1014.
28. Navas, M.C., A. Fuchs, E. Schvoerer, et al. 2002. Dendritic cell susceptibility to hepatitis C virus genotype type 1 infection. J. Med. Virol. 67:152-161.
29. Nelson, D.R., C.G. Marousis, G.L. Davis, et al. 1997. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol. 158:1473-1481.
30. Panasiuk, A., D. Prokopowicz, J. Kac, et al. 2003. Peripheral blood T, B and NK cells in relation to histological he-patitis activity and fibrosis stage in chronic hepatitis C. Hepatogastroenterology 50:178-182.
31. Plum, J., M. De Smedt, G. Leclercq, et al. 1996. Interleukin-7 is a critical growth factor in early human T-cell development. Blood 88:4239-4245.
32. Poynard, T., P. Marcellin, S.S. Lee, et al. 1998. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 4 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
33. Poynard, T., J. McHutchinson, Z. Goodman, et al. 2000. Is an "à la carte" combination interferon alpha-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31:211-218.
34. Streiff, M.B., S. Mehta, and D.L. Thomas. 2002. Peripheral blood count abnormalities among patients with hepatitis C in the united states. Hepatology 25:947-952.
35. Taki, S. 2002. Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice. Cytokine Growth Factor Rev. 13:379-391.
36. Tan, J.T., E. Dudl, E. LeRoy, et al. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA 98:8732-8737.
37. Viallard, J.F., C. Bloch-Michel, M. Neau-Cransac, et al. 2001. HLA-DR expression on lymphocytes subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 125:485-491.
38. Wasley, A., and M.J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 20:1-16.
39. Wejstal, R., G. Norkrans, R. Lenkei, et al. 1992. Peripheral blood lymphocyte subsets in patients with chronic hepatitis C - effects of interferon treatment. Liver 12: 161-167.
40. Xuhuai, J., R. Cheung, S. Cooper, et al. 2003. Interferon alpha regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37: 610-621.
41. Yamada, G., M. Takani, M. Takahashi, et al. 1995. Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22:1351-1354.
42. Zeuzem, S., J.H. Lee, A. Franke, et al. 1998. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 27: 1149-1156.
43. Navas, M.C., A. Fuchs, E. Schvoerer, et al. 2002. Dendritic cell susceptibility to hepatitis C virus genotype type 1 infection. J. Med. Virol. 67:152-161.
44. Bain, C., A. Fatmi, F. Zoulim, et al. 2001. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120:512-524.
45. Luft, T., K.C. Pang, E. Thomas, et al. 1998. Type I IFNs-alpha enhances the terminal differenciation of dendritic cells. J. Immunol. 161:1947-1953.